We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.00 | -2.15% | 45.50 | 45.00 | 46.00 | 46.50 | 44.75 | 46.50 | 4,092,357 | 16:04:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.29 | 129.04M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/5/2024 16:35 | Whitey and Tratante ...Batman n Robin.I see the Non- Magnificent 7 are on cracking form. Ps Whitey , why are u STILL here? Another fake leaving post the other day. Have a lovely weekend ... | amanitaangelicus | |
03/5/2024 16:02 | Blue finish | countbasie1 | |
03/5/2024 10:50 | AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders-DIVIDEN | blackhorse23 | |
03/5/2024 10:49 | Yes mate , money moved to APH | blackhorse23 | |
03/5/2024 09:47 | Strong sell. | blueball | |
02/5/2024 17:41 | > Trat ...please dont get too excited by your 7 upticksAman, I'm not at all excited by upticks, indeed I hadn't noticed them. > Enjoy the adulation. I'm certainly not looking for adulation, just giving my alternative opinion in response to your comment - isn't that what the board is for?> Oh yes, you wont be here long like many of the fake lth.s I'm not a fake LTH, I've been in Avacta for long time, since before the LFT was a glimmer in AS's eye. I seldom post as, to be honest, there isn't much useful discussion, mostly people parading egos and slagging each other off. Quod erat demonstrandum! | tratante | |
01/5/2024 17:07 | Doubt it, they would have said so with some words like AS realises the TX division now requires the leadership of a cancer expert and clinician. | tratante | |
01/5/2024 16:40 | Not sure they'd get much for him.! | filthypoor | |
01/5/2024 16:20 | Is the plan that AS goes with the DX division ? | fieldhouse | |
01/5/2024 16:20 | Is the plan that AS goes with the DX division ? | fieldhouse | |
01/5/2024 15:34 | Where do you think he's been exaggerating the data? We got the same messages yesterday from the new CEO, in some cases using the same slides. I agree it's a strange unexplained exit, but not for that reason. | tratante | |
01/5/2024 13:54 | He.ll be selling his share pile like a gd un. Shroomed! | amanitaangelicus | |
01/5/2024 13:53 | When will Smith own up that he.s been exaggerating data? Gone...no fanfare, nothing. Smiths bn found out i reckon. Blagger. | amanitaangelicus | |
01/5/2024 11:39 | With around 18 months of cash, this gives the upper hand to license partners to negotiate hard. | northwards | |
01/5/2024 10:23 | Hand on my heart, I can see this at 25 to 30p within a year | dan_the_epic | |
01/5/2024 10:08 | owf, A good financial summary. I don't disagree. I think the science is good and i hope the company can now progress asap. The unknown,unknowns are the problem | fieldhouse | |
01/5/2024 08:33 | Better to sell at 44p than nothing in a few months when they come cash calling if they have what they say like any intelligent person this would have been bought out months ago. It's a French Scam | goforgold1 | |
01/5/2024 08:17 | Whitey, come back pulease! I.ll give you 24hrs. Good boy. Your dim acolytes are lining the roads. | amanitaangelicus | |
30/4/2024 20:02 | PW Any other AIM lists it as CEO resigns. Typical Avacta even tried to hide that. On the point of info to shareholders, Avacta have been probably the most prolific RNS company I’ve seen, constantly spinning anything they can, over and over. I suspect (if they are to be responsible now), that news events will drop and less spin. That will better serve shareholders, not this high 5 constant pump that has been going on over far from impressive good data. Quite clearly Arisaph wanted higher safety and materially better efficacy, which one might expect from concentrated doses. Results on efficacy are very poor, less than dox original studies. Glossed up as a game changer. New hype planned by the look of it but much damage done to avid followers. Pack the suitcases, get on another flight. | ohwhatfun | |
30/4/2024 18:17 | So they've kicked Smith out and replaced him with Coughlin. I think there's more to this than meets the eye. A whole lot of narrative on her and just a short standard thank you to Smith, almost an afterthought. It will be interesting to see if there's any quicker progress with anything other than what must be the longest Phase 1 trial in history, if there is or a change of direction. | 1347 | |
30/4/2024 17:39 | Someone happy to buy half a million at 47.2 just after the bell !! | fieldhouse |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions